
Novavax (NVAX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Novavax (NVAX) last issued guidance on November 5, 2026 for fiscal year 2026. The company guided revenue in the range of $385M - $415M for the period.
Compared to prior guidance, Novavax raised its revenue forecast from a prior range of $235M - $275M.
Novavax has issued 18 guidance updates between December 14, 2022 and November 5, 2026. During this period, the company raised its outlook 6 times and lowered it 9 times, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.35 | $-0.37 | $-0.23 | $-0.56 |
| Actual | $-0.19 | $-0.32 | $-0.06 | $0.11 |
| Surprise | +45.7% | +13.5% | +73.9% | +119.6% |
| Revenue | ||||
| Estimate | $50.5M | $51.7M | $76.9M | $85.5M |
| Actual | $68.3M | $56.7M | $139.5M | $147.1M |
| Surprise | +35.4% | +9.76% | +81.5% | +72.0% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.50 | $-0.31 | $0.13 | $-0.38 |
| Revenue | ||||
| Consensus | $203.1M | $18.9M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $-0.19 | $-0.35 | 45.7 % |
| Q2 | Aug 6, 2026 | $-0.32 | $-0.37 | 13.5 % |
| Q1 | May 6, 2026 | $-0.06 | $-0.23 | 73.9 % |
| Q4 | Feb 26, 2026 | $0.11 | $-0.56 | 119.6 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $68.30M | $50.46M | 35.4 % |
| Q2 | Aug 6, 2026 | $56.70M | $51.66M | 9.76 % |
| Q1 | May 6, 2026 | $139.51M | $76.87M | 81.5 % |
| Q4 | Feb 26, 2026 | $147.14M | $85.52M | 72.0 % |